Vogenx Common Stock (VOGX)
NasdaqGM: VOGX
· Precio en tiempo real · USD
14.78
+0.69 (4.90%)
Al cierre: Aug 14, 2026, 3:29 PM
14.78
+0.00%
Fuera de horario: 7:34 PM
Vogenx Common Stock (VOGX) Stock Price, Analysis & Data
4.90% (1D)
| Precio de compra | n/a |
| Capitalización de mercado | 205.53M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -1.56M |
| Beta | n/a |
| EPS (TTM) | -0.2 |
| Ratio PER (TTM) | n/a |
| Adelante PE | n/a |
| P/B (TTM) | -55.56 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | n/a |
| Volumen | 34,379 |
| Volumen medio (20D) | 267,400 |
| Abierto | 14.34 |
| Anterior Cerrar | 14.09 |
| Rango del día | 13.50 - 16.65 |
| Rango de 52 semanas | 12.95 - 16.65 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de VOGX
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorpora...
Industria Biotechnology
Sector Healthcare
IPO Fecha Aug 12, 2026
Empleados 4
Bolsa de Valores NasdaqGM
Símbolo bursátil VOGX
Sitio web https://vogenx.com
Desempeño financiero
En 2025, los ingresos de Vogenx Common Stock fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -1.45M, una disminución de -34.4%.
Estados financieros